Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Vera Therapeutics (NASDAQ:VERA) had its price objective increased by JPMorgan Chase & Co. from $72.00 to $75.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Guggenheim lifted their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. Scotiabank assumed coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $54.33.

Vera Therapeutics Trading Down 1.9 %

Shares of VERA stock opened at $48.09 on Tuesday. Vera Therapeutics has a 12-month low of $10.79 and a 12-month high of $50.78. The company has a market capitalization of $2.64 billion, a PE ratio of -21.76 and a beta of 1.03. The firm has a 50 day moving average price of $41.53 and a two-hundred day moving average price of $39.17. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, analysts predict that Vera Therapeutics will post -2.57 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In related news, Director Beth C. Seidenberg sold 1,177 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the transaction, the director now directly owns 160,376 shares of the company’s stock, valued at $6,737,395.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Marshall Fordyce sold 23,125 shares of the business’s stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the completion of the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at approximately $14,182,110.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the sale, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 104,398 shares of company stock valued at $4,376,163. Company insiders own 21.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after purchasing an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Vera Therapeutics in the second quarter valued at approximately $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics during the second quarter worth $163,000. Ameritas Investment Partners Inc. increased its holdings in shares of Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after buying an additional 688 shares in the last quarter. Finally, Cetera Advisors LLC bought a new position in shares of Vera Therapeutics in the 1st quarter valued at $235,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.